China-based Triastek Inc., a leading pharmaceutical-focused 3D printing company, has entered into a partnership with German pharmaceutical giant Boehringer Ingelheim. The collaboration aims to explore the application of 3D printing in the development of new chemical entity (NCE) drug dosage forms, although no financial details were disclosed.
Triastek’s Technology and Contributions
Triastek utilizes its proprietary MED 3D printing technology to design the structure of pharmaceutical preparations. This technology enables the development of various prototype preparations and facilitates the exploration of dose design and release behavior of new compound molecules. The goal is to accelerate new drug development and increase success rates.
Previous Collaboration and Achievements
The company has previously been involved in Boehringer Ingelheim’s global opnMe program, where MED technology was successfully applied to improve the drugability of insoluble drugs. This involved achieving in vitro solubilization and enhancing bioavailability in animals, demonstrating the potential of 3D printing in pharmaceutical innovation.-Fineline Info & Tech
